Argenx SE (Euronext + Nasdaq: ARGX)

https://www.argen-x.com

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates. *

	Start	2019-03-28 renamed before
	Group	Argenx (Argen-X) (Group)
	Predecessor	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Industry	therapeutic antibody
	Industry 2	SIMPLE Antibody™ discovery platform
	Person	Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
	Person 2	Gubitz, Karl (Argenx 202106– CFO before at Pfizer since 2003 before PircewaterhouseCoopers)

	Region	Breda
	Country	Netherlands
	Street	5 Willemstraat
	City	4811 AH Breda
		Address record changed: 2020-12-02

Basic data	Employees	E: 501 to 1,000 (2022-03-01)
	Currency	USD
	Annual sales	539,418,000 (income, operating, consolidated (2021) 2021-12-31)
	Profit	-408,265,000 (2021-12-31)
	Cash	2,336,728,000 (2021-12-31)

		* Document for »About Section«: Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent.

		Record changed: 2024-02-12